|
|
|
18.03.25 - 09:06
|
Sofinnova Partners Exceeds Target With €165M Biotech Acceleration Fund, Europe′s Largest, With Strong Pharma Support (Business Wire)
|
|
|
Biovelocita II attracts robust support from leading pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures
The fund has already screened over 300 projects and made several investments into new companies to catalyze transformative innovation in biotechnology
PARIS--(BUSINESS WIRE)--Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Biovelocita II. The fund has exceeded its target, successfully raising €165M, with substantial backing from the top global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. This milestone marks a significant expansion of Sofinnova's biotech acceleration strategy, extending beyond Italy to include France, the United Kingdom, and Denmark, with ambitions to further reach additional European countries in the future.
Since its launch, the fund has screened over 300 projects and made several key...
|
|
|
|
|
|
|
13.03.25 - 12:03
|
Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025 (Business Wire)
|
|
|
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2025 on Thursday, April 24, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.
Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call.
A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X, YouTube, Facebook and Instagram.
corporatefinancial-news
Contacts
Media...
|
|
|
|
|
|
|
|
|
|
|
|
|
11.03.25 - 03:18
|
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb (Business Wire)
|
|
|
$5.00 per share, all-cash transaction
Expected to close in the second quarter of 2025, subject to customary closing conditions
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025.
“A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living with multiple myeloma and maximizing value for all stakeholders,” said Chip Baird, chief executive officer, 2seventy bio. “The strategic rationale for this acquisition is clear and today's announcement represents the culmination of the journey for 2seventy bio. We believe that ...
|
|
|
|
|
10.03.25 - 21:33
|
Redwire Corporation Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
|
|
|
Revenues for full year 2024 increased 24.7% year-over-year to $304.1 million
2024 accomplishments included securing a follow-on order of Roll-Out Solar Arrays for Thales Alenia Space, receiving a DARPA prime contract for our SabreSat VLEO platform, and launching 27 PIL-BOXes for our partners including Bristol Myers Squibb, Eli Lilly, and ExesaLibero Pharma
In January 2025, announced agreement to acquire Edge Autonomy in a transformational transaction that is expected to create a multi-domain, scaled and profitable space and defense tech company
Significant sequential increase in net cash provided by operations to positive $7.1 million and Free Cash Flow1 to positive $3.0 million for the fourth quarter of 2024
Net Loss for full year 2024 was $(114.3) million and Adjusted EBITDA1 for full year 2024 was $(0.8) million
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW, the “Company”), a leader in space infrastructure for the next generation space economy, today announced results for its ...
|
|
|
|
|
|
|
|
|
|
|
|
|
06.03.25 - 12:00
|
Evotec: Zahlen-Schock in Kürze? (Sharedeals)
|
|
|
Die Evotec-Aktie hatte trotz einer operativer Erfolgsnews wie einer neuerlichen Meilensteinzahlung von Partner Bristol-Myers einen katastrophalen Start in den Monat März. Verunsicherung schafft unter anderem das Aussscheiden von Finanzchefin Laetitia Rouxel. Mit Blick auf die Aussagen von CEO Dr. Christian Wojczewski sollten sich etwaige Sorgen aber als unbegründet erweisen. So habe Rouxel zu der Erreichung […]
The post Evotec: Zahlen-Schock in Kürze? first appeared on sharedeals.de....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
